These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37080895)

  • 1. Re: Hydrochlorothiazide and Prevention of Kidney-stone Recurrence.
    Veser J
    Eur Urol; 2023 Aug; 84(2):242-243. PubMed ID: 37080895
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence (NOSTONE).
    Chen DC; McVey A; Murphy DG; Eapen R; Lawrentschuk N
    Eur Urol; 2023 Sep; 84(3):353-354. PubMed ID: 37236856
    [No Abstract]   [Full Text] [Related]  

  • 3. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
    Hsi RS; Tasian G; Maalouf NM
    N Engl J Med; 2023 May; 388(21):2014-2015. PubMed ID: 37224212
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
    Lyall VS; Wood KD; Pais VM
    N Engl J Med; 2023 May; 388(21):2014. PubMed ID: 37224211
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
    Knebelmann B; Haydock L
    N Engl J Med; 2023 May; 388(21):2013-2014. PubMed ID: 37224210
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. Reply.
    Fuster DG; Bonny O; Roth B
    N Engl J Med; 2023 May; 388(21):2015-2016. PubMed ID: 37224213
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
    Dhayat NA; Bonny O; Roth B; Christe A; Ritter A; Mohebbi N; Faller N; Pellegrini L; Bedino G; Venzin RM; Grosse P; Hüsler C; Koneth I; Bucher C; Del Giorno R; Gabutti L; Mayr M; Odermatt U; Buchkremer F; Ernandez T; Stoermann-Chopard C; Teta D; Vogt B; Roumet M; Tamò L; Cereghetti GM; Trelle S; Fuster DG
    N Engl J Med; 2023 Mar; 388(9):781-791. PubMed ID: 36856614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Change in the prevention of kidney stones].
    Derouet C; Kissling S; Roth B; Bonny O; Schwotzer N
    Rev Med Suisse; 2024 Feb; 20(863):436-440. PubMed ID: 38415730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention of nephrolithiasis - Preliminary results of the Swiss Kidney Stone Cohort (SKSC) and the NOSTONE trial].
    Stritt K; Bosshard P; Bonny O; Roth B
    Rev Med Suisse; 2020 Dec; 16(717):2317-2320. PubMed ID: 33263954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int; 2023 Jul; 132(1):2-3. PubMed ID: 37340815
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term effects of low-dose thiazide and amiloride administration in recurrent renal stone formers.
    Maschio G; D'Angelo A; Fabris A; Tessitore N; Sartori L; Morbiato F; Malvasi L; Giannini S; Ferrari S; Rugiu C
    Contrib Nephrol; 1985; 49():108-17. PubMed ID: 3830560
    [No Abstract]   [Full Text] [Related]  

  • 12. Potassium citrate vs. hydrochlorothiazide to reduce urinary calcium excretion in calcium oxalate stone patients with hypercalciuria: a prospective randomized study.
    Solak V; Gökce Mİ; Yaman Ö
    Int Urol Nephrol; 2021 Sep; 53(9):1791-1796. PubMed ID: 33904027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of the patient with calcium stones.
    Yendt ER; Cohanim M
    Br J Urol; 1976; 48(7):507-14. PubMed ID: 1016824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones.
    Wolfgram DF; Gundu V; Astor BC; Jhagroo RA
    Urolithiasis; 2013 Aug; 41(4):315-22. PubMed ID: 23660825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Adherence to Medications in Secondary Prevention of Urinary Tract Stones.
    Golomb D; Nevo A; Goldberg H; Ehrlich Y; Margel D; Lifshitz D
    J Endourol; 2019 Jun; 33(6):469-474. PubMed ID: 30909741
    [No Abstract]   [Full Text] [Related]  

  • 16. [Compared metabolic effects of phosphorus or hydrochlorothiazide therapy in hypercalciuric stone-formers (author's transl)].
    Dard S; Ulmann A
    Nephrologie; 1981; 2(1):4-7. PubMed ID: 7345375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of lithogenic risk in hypercalciuria: should 24-hour urine calcium be measured?].
    Ulmann A
    Nephrologie; 1984; 5(5):232-4. PubMed ID: 6531063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of idiopathic calcium nephrolithiasis.
    Surian M; Malberti F; Colussi G; De Ferrari ME; Rombolà G; Benazzi E; Minetti L
    Contrib Nephrol; 1987; 58():172-5. PubMed ID: 3691120
    [No Abstract]   [Full Text] [Related]  

  • 19. Urine Calcium and Bone Mineral Density in Calcium Stone-Forming Patients Treated with Alendronate and Hydrochlorothiazide.
    Arrabal-Martín M; González-Torres S; Cano-García MD; De Haro-Muñoz T; Abad-Menor F; Arrabal-Polo MÁ; Cózar-Olmo JM
    Urol Int; 2016; 97(3):292-298. PubMed ID: 26800461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years' experience with the use of thiazides in the prevention of kidney stones.
    Yendt ER; Cohanim M
    Trans Am Clin Climatol Assoc; 1974; 85():65-75. PubMed ID: 4804100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.